202 related articles for article (PubMed ID: 25264232)
1. Factors affecting the success of glucagon delivered during an automated closed-loop system in type 1 diabetes.
Bakhtiani PA; El Youssef J; Duell AK; Branigan DL; Jacobs PG; Lasarev MR; Castle JR; Ward WK
J Diabetes Complications; 2015; 29(1):93-8. PubMed ID: 25264232
[TBL] [Abstract][Full Text] [Related]
2. Factors influencing the effectiveness of glucagon for preventing hypoglycemia.
Castle JR; Engle JM; El Youssef J; Massoud RG; Ward WK
J Diabetes Sci Technol; 2010 Nov; 4(6):1305-10. PubMed ID: 21129324
[TBL] [Abstract][Full Text] [Related]
3. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.
Haidar A; Legault L; Dallaire M; Alkhateeb A; Coriati A; Messier V; Cheng P; Millette M; Boulet B; Rabasa-Lhoret R
CMAJ; 2013 Mar; 185(4):297-305. PubMed ID: 23359039
[TBL] [Abstract][Full Text] [Related]
4. Dual-Hormone Closed-Loop System Using a Liquid Stable Glucagon Formulation Versus Insulin-Only Closed-Loop System Compared With a Predictive Low Glucose Suspend System: An Open-Label, Outpatient, Single-Center, Crossover, Randomized Controlled Trial.
Wilson LM; Jacobs PG; Ramsey KL; Resalat N; Reddy R; Branigan D; Leitschuh J; Gabo V; Guillot F; Senf B; El Youssef J; Steineck IIK; Tyler NS; Castle JR
Diabetes Care; 2020 Nov; 43(11):2721-2729. PubMed ID: 32907828
[TBL] [Abstract][Full Text] [Related]
5. Safe glycemic management during closed-loop treatment of type 1 diabetes: the role of glucagon, use of multiple sensors, and compensation for stress hyperglycemia.
Ward WK; Castle JR; El Youssef J
J Diabetes Sci Technol; 2011 Nov; 5(6):1373-80. PubMed ID: 22226254
[TBL] [Abstract][Full Text] [Related]
6. Efficacy determinants of subcutaneous microdose glucagon during closed-loop control.
Russell SJ; El-Khatib FH; Nathan DM; Damiano ER
J Diabetes Sci Technol; 2010 Nov; 4(6):1288-304. PubMed ID: 21129323
[TBL] [Abstract][Full Text] [Related]
7. Automated hybrid closed-loop control with a proportional-integral-derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance.
Ly TT; Weinzimer SA; Maahs DM; Sherr JL; Roy A; Grosman B; Cantwell M; Kurtz N; Carria L; Messer L; von Eyben R; Buckingham BA
Pediatr Diabetes; 2017 Aug; 18(5):348-355. PubMed ID: 27191182
[TBL] [Abstract][Full Text] [Related]
8. Quantification of the glycemic response to microdoses of subcutaneous glucagon at varying insulin levels.
El Youssef J; Castle JR; Bakhtiani PA; Haidar A; Branigan DL; Breen M; Ward WK
Diabetes Care; 2014 Nov; 37(11):3054-60. PubMed ID: 25139882
[TBL] [Abstract][Full Text] [Related]
9. Randomized Outpatient Trial of Single- and Dual-Hormone Closed-Loop Systems That Adapt to Exercise Using Wearable Sensors.
Castle JR; El Youssef J; Wilson LM; Reddy R; Resalat N; Branigan D; Ramsey K; Leitschuh J; Rajhbeharrysingh U; Senf B; Sugerman SM; Gabo V; Jacobs PG
Diabetes Care; 2018 Jul; 41(7):1471-1477. PubMed ID: 29752345
[TBL] [Abstract][Full Text] [Related]
10. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas.
Weinzimer SA; Steil GM; Swan KL; Dziura J; Kurtz N; Tamborlane WV
Diabetes Care; 2008 May; 31(5):934-9. PubMed ID: 18252903
[TBL] [Abstract][Full Text] [Related]
11. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes.
Castle JR; Engle JM; El Youssef J; Massoud RG; Yuen KC; Kagan R; Ward WK
Diabetes Care; 2010 Jun; 33(6):1282-7. PubMed ID: 20332355
[TBL] [Abstract][Full Text] [Related]
12. Day-and-Night Closed-Loop Insulin Delivery in a Broad Population of Pregnant Women With Type 1 Diabetes: A Randomized Controlled Crossover Trial.
Stewart ZA; Wilinska ME; Hartnell S; O'Neil LK; Rayman G; Scott EM; Barnard K; Farrington C; Hovorka R; Murphy HR
Diabetes Care; 2018 Jul; 41(7):1391-1399. PubMed ID: 29535135
[TBL] [Abstract][Full Text] [Related]
13. The "Glucositter" overnight automated closed loop system for type 1 diabetes: a randomized crossover trial.
Nimri R; Danne T; Kordonouri O; Atlas E; Bratina N; Biester T; Avbelj M; Miller S; Muller I; Phillip M; Battelino T
Pediatr Diabetes; 2013 May; 14(3):159-67. PubMed ID: 23448393
[TBL] [Abstract][Full Text] [Related]
14. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
[TBL] [Abstract][Full Text] [Related]
15. Role of Dual-Hormone Closed-Loop Delivery System in the Future.
Bally L; Thabit H; Hovorka R
Diabetes Technol Ther; 2016 Aug; 18(8):452-4. PubMed ID: 27500812
[No Abstract] [Full Text] [Related]
16. Cross-Validation of a Glucose-Insulin-Glucagon Pharmacodynamics Model for Simulation Using Data From Patients With Type 1 Diabetes.
Wendt SL; Ranjan A; Møller JK; Schmidt S; Knudsen CB; Holst JJ; Madsbad S; Madsen H; Nørgaard K; Jørgensen JB
J Diabetes Sci Technol; 2017 Nov; 11(6):1101-1111. PubMed ID: 28654314
[TBL] [Abstract][Full Text] [Related]
17. Development of a fully automated closed loop artificial pancreas control system with dual pump delivery of insulin and glucagon.
Jacobs PG; El Youssef J; Castle JR; Engle JM; Branigan DL; Johnson P; Massoud R; Kamath A; Ward WK
Annu Int Conf IEEE Eng Med Biol Soc; 2011; 2011():397-400. PubMed ID: 22254332
[TBL] [Abstract][Full Text] [Related]
18. Mini-Dose Glucagon as a Novel Approach to Prevent Exercise-Induced Hypoglycemia in Type 1 Diabetes.
Rickels MR; DuBose SN; Toschi E; Beck RW; Verdejo AS; Wolpert H; Cummins MJ; Newswanger B; Riddell MC;
Diabetes Care; 2018 Sep; 41(9):1909-1916. PubMed ID: 29776987
[TBL] [Abstract][Full Text] [Related]
19. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes.
Ranjan A; Schmidt S; Madsbad S; Holst JJ; Nørgaard K
Diabetes Obes Metab; 2016 Apr; 18(4):410-8. PubMed ID: 26743775
[TBL] [Abstract][Full Text] [Related]
20. Use of Sitagliptin With Closed-Loop Technology to Decrease Postprandial Blood Glucose in Type 1 Diabetes.
Underland LJ; Ilkowitz JT; Katikaneni R; Dowd A; Heptulla RA
J Diabetes Sci Technol; 2017 May; 11(3):602-610. PubMed ID: 28349708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
